Art

J-GLOBAL ID：201402278589073380   Reference number：14A0299397

Clinical utility of newly developed immunoassays for serum concentrations of adalimumab and anti-adalimumab antibodies in patients with Crohn’s disease

Crohn病患者におけるアダリムマブおよび抗アダリムマブ抗体の血清濃度に対する新規開発免疫アッセイの臨床的有用性

Author (8)： IMAEDA Hirotsugu (Shiga Univ. of Medical Sci., Dep. of Medicine, Seta-Tukinowa, 520-2192, Otsu, JPN) ,  TAKAHASHI Kenichiro (Shiga Univ. of Medical Sci., Div. of Mucosal Immunology, Graduate School, Seta-Tukinowa, 520-2192, Otsu, JPN) ,  FUJIMOTO Takehide (Shiga Univ. of Medical Sci., Div. of Mucosal Immunology, Graduate School, Seta-Tukinowa, 520-2192, Otsu, JPN) ,  BAMBA Shigeki (Shiga Univ. of Medical Sci., Dep. of Medicine, Seta-Tukinowa, 520-2192, Otsu, JPN) ,  TSUJIKAWA Tomoyuki (Shiga Univ. of Medical Sci., Dep. of Medicine, Seta-Tukinowa, 520-2192, Otsu, JPN) ,  SASAKI Masaya (Shiga Univ. of Medical Sci., Dep. of Medicine, Seta-Tukinowa, 520-2192, Otsu, JPN) ,  FUJIYAMA Yoshihide (Shiga Univ. of Medical Sci., Dep. of Medicine, Seta-Tukinowa, 520-2192, Otsu, JPN) ,  ANDOH Akira (Shiga Univ. of Medical Sci., Div. of Mucosal Immunology, Graduate School, Seta-Tukinowa, 520-2192, Otsu, JPN)
Material： Journal of Gastroenterology  (J Gastroenterol)
Volume： 49  Issue： 1  Page： 100-109  Publication year： Jan. 2014 
JST Material Number： Z0748A  ISSN： 0944-1174  Document type： Article
Article type： 原著論文  Country of issue： Germany, Federal Republic of (DEU)  Language： ENGLISH (EN)

Thesaurus term： human(primates) ,...
Semi thesaurus term： *adalimumab ,...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=14A0299397&from=J-GLOBAL&jstjournalNo=Z0748A") }}

JST classification (2)： Drug therapy(=pharmacotherapy)for digestive system diseases  (GH05020G) ,  Bioassay  (EA03060N)

Reference (34)：

• Danese S, Colombel JF, Reinisch W, et al. Review article: infliximab for Crohn's disease treatment-shifting therapeutic strategies after 10 years of clinical experience. Aliment Pharmacol Ther. 2011;33:857-69.
• Mayer L. Evolving paradigms in the pathogenesis of IBD. J Gastroenterol. 2010;45:9-16.
• Hanauer SB, Kornbluth AA, Messick J, et al. Clinical scenarios in IBD: optimizing the use of conventional and biologic agents. Inflamm Bowel Dis. 2010;16(Suppl 1):S1-11.
• Andoh A, Kuzuoka H, Tsujikawa T, et al. Multicenter analysis of fecal microbiota profiles in Japanese patients with Crohn's disease. J Gastroenterol. 2012;47:1298-307.
• Allez M, Vermeire S, Mozziconacci N, et al. The efficacy and safety of a third anti-TNF monoclonal antibody in Crohn's disease after failure of two other anti-TNF antibodies. Aliment Pharmacol Ther. 2010;31:92-101.

Terms in the title (8)： Crohn病 ,  患者 ,  アダリムマブ ,  抗体 ,  血清濃度 ,  開発 ,  免疫アッセイ ,  臨床的有用性